Multiple system atrophy
Drug research and approvals for multiple system atrophy: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 17, 2026, 95 studies of multiple system atrophy are recruiting on ClinicalTrials.gov, Health Canada has authorized 2 drug trials for it since 2013, and FDA has 0 approved and 9 open orphan designations naming it.
- Recruiting worldwide: 95
- Trials authorized in Canada: 2
- FDA orphan approvals: 0
- EU medicines: 0
Recruiting Now
Newest start dates first, of 95 recruiting on ClinicalTrials.gov ↗- Metabolomic Biomarkers of Myotonic DystrophyNCT07912983 · Not reported · Massachusetts General Hospital · starts Oct 26, 2026
- Tributyrin for Progressive Supranuclear Palsy (PSP): Virtual TrialNCT07863180 · Phase 1 / Phase 2 · Prabesh Kanel · starts Oct 1, 2026
- A Trial to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of SFL-0821 in…NCT07798609 · Phase 1 / Phase 2 · Soufflé Therapeutics, Inc. · starts Sep 1, 2026
- Efficacy and Safety of Butylphthalide in the Treatment of Multiple System AtrophyNCT07518810 · Phase 2 / Phase 3 · Second Affiliated Hospital, Zhejiang University, School of Medicine · starts Aug 27, 2026
- Test-retest Trial With [11C]MODAG-005 in PD or MSA and AMHC - Pilot PhaseNCT07640542 · Early Phase 1 · MODAG GmbH · starts Jul 29, 2026
- A Study of Risdiplam in Participants With Type I and Type II Spinal Muscle Atrophy (SMA)NCT07531719 · Not reported · Hoffmann-La Roche · starts Jul 22, 2026
- Comparison of Individuals With Primary Ciliary Dyskinesia and Healthy ControlsNCT07740551 · Not reported · Izmir Democracy University · starts Jun 16, 2026
- A Study to Evaluate Satety, Tolerability, Biodistribution, Radiation Dosimetry, and Pharmacokinetics of SST001 in…NCT07604116 · Phase 1 · Synusight Biotech (Shanghai) Co., Ltd. · starts Jun 15, 2026
- Expansion Study of ALT001 in Patients With Multiple System AtrophyNCT07476352 · Early Phase 1 · yilong Wang · starts Jun 15, 2026
- The Study of Safety and Preliminary Efficacy of ALT001 in Patients With MultIple System Atrophy-Cerebellar TypeNCT07514923 · Early Phase 1 · yilong Wang · starts Jun 10, 2026
Drug Pipeline
2 approved, 5 in phase 3, 12 in phase 2, 1 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this conditionApproved: Droxidopa, Ioflupane
- Verdiperstat
- Phase 3 Myeloperoxidase inhibitor
- Rifampin
- Phase 3 Bacterial DNA-directed RNA polymerase inhibitor
- Riluzole
- Phase 3 Sodium channel alpha subunit blocker
- Ampreloxetine
- Phase 3 Norepinephrine transporter inhibitor
- Epigalocatechin gallate
- Phase 3
- Exenatide
- Phase 2 Glucagon-like peptide 1 receptor agonist
- Fluoxetine
- Phase 2 Serotonin transporter inhibitor
- Lithium carbonate
- Phase 2 Inositol-1(or 4)-monophosphatase 1 inhibitor
- Sirolimus
- Phase 2 FK506-binding protein 1A inhibitor
- Insulin human
- Phase 2 Insulin receptor agonist
- Human immunoglobulin g
- Phase 2 Replacement therapy, immunomodulatory effects
- Rasagiline
- Phase 2 Monoamine oxidase B inhibitor
- Safinamide
- Phase 2 Monoamine oxidase B inhibitor
- Inosine
- Phase 2
- Amlenetug
- Phase 2
- Indenebart
- Phase 2
- PBT-434
- Phase 2
- Pseudoephedrine
- Early phase 1 Norepinephrine transporter releasing agent
How Its Trials Ended
179 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 26 whose ending is known, 31% met their primary endpoint, 8% missed it and 62% stopped early.
- Ongoing7542%
- Completed, result not reported6134%
- Status unknown179%
- Met its primary endpoint84%
- Stopped: other or unclear53%
- Stopped: funding42%
- Stopped: enrollment or feasibility32%
- Missed its primary endpoint21%
- Stopped: lack of efficacy21%
- Stopped: sponsor or business decision21%
Trials Authorized in Canada
Newest first; search them all in Canada trials| Dec 13, 2024 | Interventional, randomized, double-blind, placebo-controlled, optional open-label extension trial of lu af82422 in participants with multiple system atrophyLU AF82422 | H. Lundbeck A/S | Ongoing |
| Jul 12, 2023 | A phase 3, multi-center, randomized withdrawal and long-term extension study of ampreloxetine for the treatment of symptomatic neurogenic orthostatic…Ampreloxetine (TD-9855) | Theravance Biopharma Ireland Limited | Pending |
FDA Orphan Designations
Approved first, then open designations, newest first| Mar 16, 2025 | ExidavnemabTreatment of multiple system atrophy | BioArctic AB | Designated |
| Apr 30, 2024 | Human recombinant, monoclonal antibody (mAb) of the IgG1…Treatment of multiple system atrophy (MSA) | Lundbeck Pharmaceuticals LLC | Designated |
| Oct 3, 2023 | N-(4-Methyl-3-(4-(5-(4-methylisoxazol-5-yl)pyridine-3-yl)pyr…Treatment of Multiple System Atrophy | ABLi Therapeutics, Inc. | Designated |
| May 9, 2023 | AmpreloxetineTreatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy | Theravance Biopharma Ireland Limited | Designated |
| Sep 1, 2022 | 3-(1,3-benzodioxol-5-yl)-5-(3-bromophenyl)-1H-pyrazoleTreatment of Multiple System Atrophy | Teva Branded Pharmaceutical Products R&D, Inc. | Designated |
| Jul 1, 2022 | 2-[[(4-Methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-…Treatment of Multiple System Atrophy (MSA) | Dasher Neuroscience Inc. | Designated |
| Feb 15, 2019 | VerdiperstatTreatment of multiple system atrophy (MSA). | Biohaven Pharmaceuticals, Inc. | Designated |
| Jan 29, 2019 | 5,7-Dichloro-2-((ethylamino)methyl)-8-hydroxy-3-methylquinaz…Treatment of multiple system atrophy | Alterity Therapeutics, Limited | Designated |
| Jan 26, 2015 | 18Fluorine-N-3-Fluoropropyl-2beta-carbomethoxy-3beta-(4-iodo…Diagnostic to be used in the management of multiple system atrophy (MSA) | Advanced Imaging Projects, LLC | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA